Do you want to read an article? Please log in or register.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Lipids
COMMENTED
Related content
COMMENTED
Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
BMJ.
Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, Kiflen R, Quadri K, Kwon HY, Karamouzian M, Adams-Webber T, Ahmed W, Damanhoury S, Zeraatkar D, Nikolakopoulou A, Tsuyuki RT, Tian J, Yang K, Guyatt GH, Johnston BC
doi: 10.1136/bmj.m696.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials
Diabetes Obes Metab.
Huang CJ, Wang WT, Sung SH, Chen CH, Lip GY, Cheng HM, Chiang CE
doi: 10.1111/dom.13342.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials
Diabetes Care.
Kaul S
doi: 10.2337/
Diabetes - General
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials
Eur Heart J.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S
doi: 10.1093/eurheartj/ehy808.
COMMENTED
Type 2 Diabetes
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Lancet Diabetes Endocrinol.
Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B
doi: 10.1016/S2213-
Diabetes - General
Long-Term Absolute Risk for Cardiovascular Disease Stratified by Fasting Glucose Level
Diabetes Care.
Bancks MP, Ning H, Allen NB, Bertoni AG, Carnethon MR, Correa A, Echouffo Tcheugui JB, Lange LA, Lloyd-Jones DM, Wilkins JT
doi: 10.2337/dc18-1773.
COMMENTED
Type 2 Diabetes
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-2251.
Diabetes - GeneralType 2 Diabetes
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
Diabetes Care.
Basu S, Raghavan S, Wexler DJ, Berkowitz SA
doi: 10.2337/dc17-2252.
COMMENTED
Diabetes - General
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk
Eur Heart J.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S
doi: 10.1093/eurheartj/ehz149.